Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
YKR0003
- Development stage
- Preclinical
- Lead developer
- Beijing Yingkerei Pharmaceutical Technology
- Administration
- Inhalation
01
Overview
YKR0003 is a traditional Chinese medicine (TCM) candidate developed by Beijing Yingkerei Pharmaceutical Technology, primarily targeted for the treatment of respiratory conditions such as bronchial asthma. Developed using Yingkerei's proprietary technology for modernizing traditional formulations, the candidate is designed for delivery via nebulized inhalation. This route of administration is intended to improve local bioavailability in the respiratory tract and provide rapid therapeutic action while minimizing systemic side effects. YKR0003 is currently in the preclinical stage of development and is positioned within the company's portfolio for technology transfer and collaborative clinical advancement.
Beyond the preview
Go deeper on YKR0003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on YKR0003.